<DOC>
	<DOC>NCT02663739</DOC>
	<brief_summary>The study is a post-market surveillance study required by Japanese Regulatory Authorities as a condition of approval</brief_summary>
	<brief_title>ZenithÂ® TXD Post-market Surveillance in Japan</brief_title>
	<detailed_description />
	<criteria>Patients with thoracic aortic dissection, including attempted cases Patients with acute Stanford type B aortic dissection, including attempted cases Stanford type A aortic dissection and/or chronic type B aortic dissection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stanford type B aortic dissection</keyword>
	<keyword>Malperfusion</keyword>
	<keyword>Rupture</keyword>
	<keyword>Acute disease</keyword>
	<keyword>Endovascular procedures</keyword>
</DOC>